{"name":"Multitude Therapeutics Inc.","slug":"multitude-therapeutics-inc","ticker":"","exchange":"","domain":"multitude.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"AMT-151","genericName":"AMT-151","slug":"amt-151","indication":"Other","status":"phase_1"},{"name":"AMT-562","genericName":"AMT-562","slug":"amt-562","indication":"Other","status":"phase_1"},{"name":"AMT-116","genericName":"AMT-116","slug":"amt-116","indication":"Other","status":"phase_1"},{"name":"AMT-253","genericName":"AMT-253","slug":"amt-253","indication":"Other","status":"phase_1"},{"name":"AMT-253 for injection","genericName":"AMT-253 for injection","slug":"amt-253-for-injection","indication":"Other","status":"phase_1"},{"name":"AMT-676","genericName":"AMT-676","slug":"amt-676","indication":"Secondary hyperparathyroidism in patients with chronic kidney disease","status":"phase_2"}]}],"pipeline":[{"name":"AMT-151","genericName":"AMT-151","slug":"amt-151","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMT-562","genericName":"AMT-562","slug":"amt-562","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMT-116","genericName":"AMT-116","slug":"amt-116","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMT-253","genericName":"AMT-253","slug":"amt-253","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMT-253 for injection","genericName":"AMT-253 for injection","slug":"amt-253-for-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMT-676","genericName":"AMT-676","slug":"amt-676","phase":"phase_2","mechanism":"AMT-676 is a small-molecule allosteric modulator of the calcium-sensing receptor (CaSR) that enhances receptor sensitivity to extracellular calcium.","indications":["Secondary hyperparathyroidism in patients with chronic kidney disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPbGQ2ZjVkM3RPV0RkbTdVbnhHMnlVMlpoaDk2dVlBZVJ6ZFhCWWFURWJvbHVfV1A4cjRkR3UwNXV4SGZ5Yl9nRV9XZ0hYVW1sM3dqZHlVNGV3S1hHRXZlZTV3UVZlTnlHbEZ3RjItdnYyRWZLNkVkM0RzTURyRktoemJnbUxyNW1zamtySmFhZXVlTER4UDRoRjI0Yno?oc=5","date":"2026-03-18","type":"trial","source":"openPR.com","summary":"Endometrial Cancer Clinical Trial Pipeline Accelerates as 50+ - openPR.com","headline":"Endometrial Cancer Clinical Trial Pipeline Accelerates as 50+","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOamg4YXVxMi1yYWQtVEFDbVZpU1VEV0d5bWU1VHhOTW1OdHZWWXl0d0FTeEl6cUpLaTg3S08tMGRKYnlCRnlhUExYeUQwdkNhNGVqLVVleWJRVHJzRmpQZVUwZ0hHalg5VEp5RUhkRnEzSWNpYUhmU3N4U3loN1hWbzM5X01sdGFxYjBKYy1MUWk4VDlTRm9uLVlIa2k?oc=5","date":"2026-01-02","type":"pipeline","source":"BioWorld News","summary":"ADCs’ breakout 2025 and their still-unfinished potential - BioWorld News","headline":"ADCs’ breakout 2025 and their still-unfinished potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPb0pXQXFYOS1lbHJfdVYtVzZZLVpvV0xSUEM1WXlNdXJpVVVQLXMxemJWa1d2RlVwdjZiQVozcTBKSzNmcnlBanBybVdzV2ozQ3d1VFFXZlI5emQtNkVpQm1kSTNrb3JmMGVYQVJKRElzbnZiTWM3aHdmWWxwR21IZlZpTVpXN2ROZE1zbjBEc05PUDNIT2FPWGpzQ2RGVHVLR21Z?oc=5","date":"2025-10-21","type":"pipeline","source":"BioWorld News","summary":"ADC space has plenty of room to grow, say ESMO 2025 panelists - BioWorld News","headline":"ADC space has plenty of room to grow, say ESMO 2025 panelists","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPNTFEZXpqOEhWSTVqMDZfek40b21sSDByb3VTbnVRcjU1YkhLd3A5OUNPUkpZV1FRdDlPZG5kdEpGamdNS1FTaFAtTzZXYWtxT3d6UG1wNXY1OTlGRDFXdWhONnFTWDctaGRNZXAyZkJjTWsxZ0h1N3N3dExZaTNXaDF4NUJ5Zw?oc=5","date":"2025-08-20","type":"trial","source":"Oncology Pipeline","summary":"Astellas and Amgen join the pan-KRAS push | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Astellas and Amgen join the pan-KRAS push | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQem5OTlp6NWdMZTZhdmRHa19MdEppSU1yUlhfQThWcENJbHVnS0lLNkpGQ3BuQXVoNlV4Yk5Qb1VDdjNUYkxjWl9YWXhibUJFc2dueUxqM0h1WHd3RkU5SWNZXzcteVFKSWxYM0dFOEI3bUFLRWRNR3J2N2RESXptU0hYaXd6eUxqRzBHbld2QkJXVkY4cXBoOGRxRTZtTFo0LWEtbG1NeU1TZWxmcVJGNnpFQnZJYXBMaTFvVGJ5OA?oc=5","date":"2025-07-29","type":"pipeline","source":"Fierce Pharma","summary":"Merck joins Big Pharma cost-cutting crowd, revealing plan to save $3B annually by 2027 - Fierce Pharma","headline":"Merck joins Big Pharma cost-cutting crowd, revealing plan to save $3B annually by 2027","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNN3VNR05UUlVFM2ctQ21uR2ZCcnVzWC1aSnByZXQ4Qk9yY19GMU83UEJyNlpPNUFhLUZFaFdNT2ItWHVfdDJCcE42YzhleTEwZEVjMXNUZ0pkREdaWjRIQUExSzFiXzVJNWpaZU9FYnRha25za0hPMHpOai1haHBRTnVuOUlJeWN4TjlVRdIBkgFBVV95cUxQaGxiYUpVNks0Yi1xemJLdkE1SVRKcnlkZWZja1FNc0FSa2JaSEJwY3FsZWN5WEF6Y2h6d2Rwc1Flek1kLUdpcGlRNDZBTDJoVzYtNVNmcHNOVzFsYmRnaVg1VFNwRkY3M3ZCRE50ekNYMG1SZGpkWmJ3enNmR1pIUlRMWFJsWkZWUkt6ZGU3eGZtQQ?oc=5","date":"2025-03-13","type":"pipeline","source":"BioInformant","summary":"Garuda Therapeutics Closes $50 Million Series A-1 Financing to Advance Off-the-Shelf Blood Stem Cell Therapies - BioInformant","headline":"Garuda Therapeutics Closes $50 Million Series A-1 Financing to Advance Off-the-Shelf Blood Stem Cell Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOM21NWGJUU3VHRnF1NzFjNk1RelV4RGVxWXVYN19jNGhVNjZIekt5YktjYTRBejRQeGE2VWd6V0RESG92eldPZms4RDlFZ0kxWmdtb0Z2ODFtR1ZTQWJCM0Nha0p4YXhoazJrdV9rYzVUVDlxTnAyVXRMOTdkeTR1S3ZyMDJ3TW4xU3lQa0pNY1dzeGt1R0E4Xy14bFlISWJkck1WRUdDMTFzOW5YOWlHalB5ZmpZcWR2dGxNNTEzbGhyUklaZWtWMG9fTWU1NGtPRWRIS3AyanphRFhaYmQtTGRIX21YNkRKYS1aUDNRbFFjWnN3Ti1GX3JOc3Y?oc=5","date":"2024-10-17","type":"pipeline","source":"prnewswire.com","summary":"200+ Pharma Companies Vie for the Top Spot in the Expanding Antibody-Drug Conjugate Oncology Market | DelveInsight - prnewswire.com","headline":"200+ Pharma Companies Vie for the Top Spot in the Expanding Antibody-Drug Conjugate Oncology Market | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxObjEyaGZIQS1nS21EMUFaZDB1X2xPNnNMYnV2SEpmamIzU1FlVVBMcFA3ck93UG1OaUZZNE82S3NaMFlCR2VWS3E3b0dIRWhYcVdnRDhoQ3gzcG0tVGtxU2pfbnM0ZHRzN3g0S2UxVU5fVWRRaEd3Y083a3dnMEFiOEwxdmRoZ1gzUEI1Rl93ekNCWjM0dzhsYUtDYkRXQUZzd2p0aUszS1Rfb0VRX1BQbFB3?oc=5","date":"2024-09-11","type":"pipeline","source":"Harvard Office of Technology Development","summary":"Ropirio launches from Wyss Institute to develop first-in-class lymphatic medicines - Harvard Office of Technology Development","headline":"Ropirio launches from Wyss Institute to develop first-in-class lymphatic medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOb243dHlWXzd5NUh0akdhUDFBak9WQTFnbGhsUDJQVVBLZUVIY1lyWmRhNzNyYU1PTUxGcGI1Y1FQZmxqN2txSGoyblJzSjJoVTJqOXN1RHVrWnJST1d6cXNTYXJXODRHeE1yZWpHcWNMakstX2NCaklIMjBKU2piZFNqamlPb09YamRuX0ctNkJ4RmNqOGF4YzVMNzZQSTgx?oc=5","date":"2024-08-20","type":"deal","source":"Fierce Biotech","summary":"Denmark's Adcendo signs $1B biobuck deal for Multitude’s anti-TF ADC - Fierce Biotech","headline":"Denmark's Adcendo signs $1B biobuck deal for Multitude’s anti-TF ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNQUVmemlDV25CRzU0ZXFKaXFvYzNHR3RGOHdsb3AtNk5XVlM2T0tmSTdHWDhHcjRLWDRYcG4zRXpwNS1rQm16YWhqMFVrSzlzb2VtRERtZkh6eHRtOUJ3WGYxcDN1cUh4b19ZRzdiSkpNLUhGTlc0eXZqbTZRVWMyZXQ2aTdtdDJJVHZ2Z18yeE0ydkdDSHd4VlBGMEE3RWZOQXc?oc=5","date":"2024-08-20","type":"deal","source":"European Biotechnology Magazine","summary":"Adcendo broadens ADC pipeline in US$1bn biobucks deal - European Biotechnology Magazine","headline":"Adcendo broadens ADC pipeline in US$1bn biobucks deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxQTWxXdGhBNGFuSk9Zc3JMOVVRTlA0cEJaTWcyOEt3aTBtZ21heFgyZEdORjFiWDFueUZHVG5Wbzl2QzE0RU1lMVg5Y1JtOVRsLVhMS0RNMjhWd1ItazFmYmtybXg3U2dsLWx4YW5NUDhTZUk0dDVzNWNJTkV4dVhRVm11bC1Oay01SHZaMktVMFlRbHA2LWNrVUFiUllxVXZlTFZVWGc2d283NXhraHVJLXhFUGoycXNLSzhWWU45ek9FX21Cb1kyalhlYkRFcEl2UGk3U1NsMG1nY0pvamdybkoxNFdUU3l3dU9EUlk1V0NhMjlOTmdTOW9zRlNvakVZbGlqSkhRN1IzakF5X2t5S2pRRTA2OUp5ZTRTWmtDMHItZm5fQ1dmc0hNMDhaUkk2VExTbUctNnMyd25GS3VwampOVkVLbjdKblZ6SEZwUGNnUjFR?oc=5","date":"2024-01-30","type":"deal","source":"prnewswire.com","summary":"WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development - prnewswire.com","headline":"WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology E","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxPN2I3YVJ5TVQyV0JLa3Awb2V6c2h0Uy04enlsTXdCcE8yckw3Q21VZmpZMjdmd2xCQkgtVHdQTEo3SEE5RkJZb0VneGpxT2RqTmVjamgyY1NuWU4tcnJ0cUlId25DZVVHczQ3VzB4WDhibzRrSzVoM0gxb3NfSU8ycVBHbVdaY2ZFcUJqbHNfUm9xMDl5OXk1RjczbF9rOWpFVUJLOHBjT19uMEJaTW93N1FVQThxVDVwWWdsb09QOVZ3SzFKSGFzS0hteUhzQ21WajNCcjM4cTBubzRndmI5QWxTaTNCb3ozSlFqdDdiQTdJTUxBTTl4cERDN3Z0R3JiV3B4Ti1fakxzcWNRQ0NYTTBiZHM1RnE4U3EtRXB6eW8yYTkxQ19LbC1objVVb3UxTDNrMDRySFBnei1zRkE?oc=5","date":"2022-05-26","type":"pipeline","source":"businesswire.com","summary":"Flagship Pioneering Unveils ProFound Therapeutics to Illuminate an Expanded Universe of Human Proteins With the Potential to Enable a Multitude of New Medicines - businesswire.com","headline":"Flagship Pioneering Unveils ProFound Therapeutics to Illuminate an Expanded Universe of Human Proteins With the Potentia","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_1":5,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}